Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $135.50 USD
Change Today 0.00 / 0.00%
Volume 0.0
BAYZF On Other Exchanges
Symbol
Exchange
Xetra
OTC US
BrsaItaliana
Continuous
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

bayer ag-reg (BAYZF) Snapshot

Open
$137.50
Previous Close
$135.50
Day High
$137.50
Day Low
$135.50
52 Week High
03/20/15 - $155.97
52 Week Low
10/15/14 - $125.60
Market Cap
112.1B
Average Volume 10 Days
636.2
EPS TTM
--
Shares Outstanding
826.9M
EX-Date
05/28/15
P/E TM
--
Dividend
$2.19
Dividend Yield
1.81%
Current Stock Chart for BAYER AG-REG (BAYZF)

bayer ag-reg (BAYZF) Related Bloomberg News

View More Bloomberg News

bayer ag-reg (BAYZF) Details

Bayer Aktiengesellschaft develops, produces, and markets health care and agricultural products, and high-tech polymer materials worldwide. The company operates through HealthCare, CropScience, and MaterialScience segments. The HealthCare segment offers prescription pharmaceuticals, such as anticoagulants; medicines to treat hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension, high blood pressure, and infectious diseases; and contraceptives, as well as provides consumer health products, including over-the-counter medications, dermatology products, nutritional supplements, veterinary medicines, and animal grooming products. This segment also provides medical care products, including blood glucose monitoring devices, such as single-strip and multi-strip systems; USB meters that feature integrated diabetes management software and direct plug-in to computers; and contrast agent injection systems for diagnostic and therapeutic medical procedures in X-ray, computed tomography, and magnetic resonance imaging. The CropScience segment offers products in the areas of seeds and plant traits, and crop protection; and products for use in gardens and non-agricultural pest control, as well as green industry. The MaterialScience segment provides high-tech polymer materials in the areas of polyurethanes, polycarbonates, coating and adhesive raw materials, and specialty chemicals; and selected inorganic basic chemicals. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

117,798 Employees
Last Reported Date: 07/29/15
Founded in 1863

bayer ag-reg (BAYZF) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €3.2M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €520.0K
Chief Strategy & Portfolio Officer and Member...
Total Annual Compensation: €2.0M
Labor Director and Member of Management Board
Total Annual Compensation: €1.6M
Member of Management Board, Chief Medical Off...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

bayer ag-reg (BAYZF) Key Developments

Bayer Group Opens its First Medical Devices Plant in Costa Rica

Bayer Group opened a plant for the production of a non-reversible permanent contraceptive device, with an investment of USD 12 million and an initial employment generation for up to 75 people. The plant located in the Zona Franca Metropolitana in Barreal de Heredia covers about 1,400 square meters, dedicated to the assembly of this medical device and has the ISO 13485 certification, which will allow Bayer to market this product in Europe and Canada. It also has the approval of the US Food and Drug Administration (FDA) to sell it in the United States.

Bayer AG Announces Directorate Changes

The Bayer AG announced the appointment of Jens Behrens as the director general and financial director of the Bayer company in Ukraine instead of Christoph Henze. Before the appointment Behrens had headed the corporate support service at the Bayer HealthCare business-group in China. He is also a member of the Bayer Global Leadership Circle group. Behrens had earlier worked for Bayer in Hong Kong, Taiwan, Japan, Europe and the United States. His total experience in the concern is over 30 years.

Bayer AG Announces Group Earnings Results for the Second Quarter of 2015; Confirms Earnings Guidance for 2015; Provides Earnings Guidance for the Remainder of the Year 2015

Bayer AG announced Group earnings results for the second quarter of 2015. Group sales climbed by 4% organically to EUR 12.1 billion, supported mainly by its HealthCare business. Reported EBIT came in 28% ahead of the prior year's quarter after net special charges of EUR 255 million, mainly comprised of integration costs, expenses for the planned stock market flotation of MaterialScience, efficiency improvements and measures to improve its production structures. Adjusted EBITDA for the group posted an increase of 33% to EUR 2.9 billion, driven by the positive business development. And then core earnings per share amounted to EUR 1.98, an increase of 34% over the prior year. As a result of the improvement in EBITDA, gross cash flow advanced 31% in the quarter. Net cash flow rose by 24% to EUR 2.0 billion, despite more funds having been tied up in working capital versus the prior year. With capital expenditures of EUR 600 million, the operating free cash flow came in at roughly EUR 1,350,000,000. The company provided earnings guidance for the remainder of the year 2015. Based on its performance in the first half, its expectations for the remainder of the year and using end-of second quarter exchange rates its guidance for sales from continuing operations in the region of EUR 47 billion. Its previous guidance was in the region of EUR 48 billion to EUR 49 billion included discontinued operations of Diabetes Care of approximately EUR 900 million. This level corresponds to a low single-digit percentage increase of its revenue on a currency- and portfolio-adjusted basis. For adjusted EBITDA, it remains its goal to increase in the high-teens percentage.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAYZF:US $135.50 USD 0.00

BAYZF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.39 USD -0.59
Allergan plc $307.44 USD -0.57
Amgen Inc $152.48 USD -3.41
GlaxoSmithKline PLC 1,341 GBp +9.50
Sanofi €88.02 EUR -0.42
View Industry Companies
 

Industry Analysis

BAYZF

Industry Average

Valuation BAYZF Industry Range
Price/Earnings 28.8x
Price/Sales 2.2x
Price/Book 4.5x
Price/Cash Flow 28.8x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAYER AG-REG, please visit www.bayer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.